Bristol-myers Company

Bristol-myers Squibb Compnay

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Sanraku-ocean Co., Ltd.

Shin Nippon Biomedical Laboratories, Ltd.

Translational Research, Ltd.

Other

Fujifilm Corporation

Toshikazu Oki

Hamao Umezawa

Tomio Takeuchi

Masataka Konishi

Takeo Miyaki

Taiji Inui

Koji Tomita

Maki Nishio

Yosuke Sawada

Masa Hamada

Masaaki Ishizuka

Hiroshi Naganawa

Mitsuaki Tsunakawa

Masatoshi Kakushima

Akihiro Yoshimoto

Yasutaro Hamagishi

Shunji Haruta

Hideo Kamei

Kyoichiro Saitoh

Osamu Tenmyo

Takashi Hanafusa

Tomoyuki Ishikura

Hiroaki Ohkuma

Seiji Iimura

Sawao Murao

Akira Takamatsu

Koko Sugawara

Masami Hatori

Norio Shibamoto

Masaru Ohbayashi

Keiko Shimizu

Toyokazu Nishino

Yutaka Hoshino

Yasue Matsuzawa

Kozo Tomatsu

Tomokazu Ueki

Kiyoshi Matsumoto

Takayuki Naito

Hajime Kamachi

Tetsuro Yamasaki

Shimpei Aburaki

Kageaki Kouno

Soichiro Toda

Takashi Tsuno

Satoshi Yamamoto

Takeo Yoshioka

Masahisa Oka

Hiroshi Tone

Yuji Nishiyama

Hiroshi Tanaka

Yasutaka Shimauchi

Tamotsu Furumai

Yasuhiro Igarashi

Masaru Sugawara

Shigeyuki Ando

Yasuo Fukagawa

Noriyuki Ohkusa

Masaaki, All Ishizuka

Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.

Compositions for nasal administration of pharmaceuticals

Compositons for nasal administration of pharmaceuticals

A dicarboxylic acid compound obtainable by oxidative degradation of pradimicin antibiotics, which are antibiotics consisting of the benzonaphthacene skeleton, a D-amino acid side chain and a sugar chain, for the second saccharide residue of the sugar chain, and use thereof utilizing a specific microorganism binding property thereof are provided. The dicarboxylic acid compound has significantly improved water-solubility compared with the raw material antibiotics, whist maintaining the specific microorganism binding property.

Benzonaphthacene glycoside derivative and use thereof

Provided is an insulin-containing granulated composition for nasal administration comprising a crystalline cellulose aggregate having a specific particle diameter distribution as a carrier. Such granulated composition for nasal administration can efficiently increase a blood insulin concentration.

Composition for nasal administration of insulin

The present invention relates to novel antifungal antibiotics herein designated as pradimicin L and pradimicin FL, and derivatives thereof. Pradimicins L and FL are produced by Actinomadura verrucosospora subsp. neohibisca strain R103-3, ATCC No. 53930.

Pradimicins l and fl, and derivatives thereof

The present invention concerns neutral sugar derivatives of pradimicins, their use as antifungal agents, methods for their preparation, and intermediates for their synthesis.

Pradimicin derivatives

Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

Antiviral antibiotic BU-3889V

The present invention relates to an arylsulfatase of microbial origin. The enzyme may be linked to an antibody against a tumor-associated antigen and the resulting conjugate used in conjuction with a sulfated prodrug of a 4'-demethylepipodophyllotoxin glucoside derivative, particularly etoposide in cancer chemotherapy.

Arylsulfatase from streptomyces

The present invention provides BU-4641V of the formula: ##STR1## This invention also provides a biologically pure culture of BU-4641V producing Arthrinium sp. FA1744. Another aspect of the invention provides a process for preparing BU-4641V. Yet further aspect of the present invention provides a method for treating mammalian tumors and bacterial or viral infections.

BU-4641V, an antibacterial, antiviral and antitumor antibiotic

The present invention relates to a novel .alpha.-glucosidase inhibitor, pradimicin Q, having the following formula ##STR1## and its pharmaceutically acceptable base salts.

Process for the preparation of .alpha.-glucosidase inhibitor, pradimicin

Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.

Method for treating fungal infections with serine analogs of BU-3608

Process for preparing antiviral antibiotic BU-3889V

The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.

BU-3420T antitumor antibiotic

Growing community of inventors

Yokohama, Japan

Toshikazu Oki